There’s too much at stake in drug development to rely on uncertainty.
We bring foresight to the forefront, turning complex data into confident direction — helping pharma innovators and investors move smarter, from investment to launch.
Who we are
We work with the people making the most complex decisions in pharma and biotech — supporting critical choices across forecasting, portfolio strategy, competitive intelligence and dealmaking.
For over three decades, Evaluate has combined deep industry expertise with rigorously curated data and thoughtful analysis to bring clarity to uncertainty. But we’re more than a data provider. We work alongside our clients as collaborators — translating insight into direction, and complexity into confidence.
Whether assessing opportunity, navigating risk or shaping long‑term strategy, our focus is the same: helping teams move forward with precision, purpose and conviction — because when decisions carry real-world consequences, experience and partnership matter.
What we do
We believe that connected data leads to a clearer picture. We help clients can make accurate, high value decisions that ensure therapies get to the patients faster. Our seamless view of the industry builds your understanding of the commercial issues that affect strategic decisions — so you can turn understanding into insight, and insight into action.
From market sizing and commercial opportunity assessment, to competitive intelligence and deal benchmarking, Evaluate is here to help. Our insights solutions put the data you need at your fingertips, while our experts are here to deliver tailored guidance.
Part of Norstella
Evaluate is proud to be part of Norstella – an organisation that unites five market-leading companies with a shared goal: to improve patient access to life-changing therapies. We are stronger together – and as Norstella company,
Evaluate plays a key role in helping you connect the dots from pipeline to patient.
Careers
Build insight and value. Improve patient outcomes.
Do you want to work with clients that have a global impact? Do you want to be part of our ongoing growth?
Explore all our opportunities.
AI Capabilities
Learn how Evaluate uses AI to help you make confident decisions faster.
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Paul leads the Evaluate’s consulting and analytics business, overseeing strategic advisory engagements across portfolio strategy, asset strategy, competitive intelligence, forecasting, valuation, and BD&L, working with clients across the global pharma and biotech ecosystem.
Paul brings extensive experience spanning academic research and life sciences consulting, supporting organizations ranging from early-stage biotech companies to large pharmaceutical corporate strategy teams. His work focuses on helping clients make evidence-based decisions across the product lifecycle, from pipeline prioritization through to commercial strategy and investment decision-making.
Mark leads client engagements focused on asset strategy, portfolio prioritization, opportunity assessment, forecasting and valuation, and development strategy across pharma and biotech portfolios. Mark brings over 25 years of biopharma and life sciences experience, having worked across academia, large pharma, and consulting roles. His background includes hands-on experience as a medicinal chemist, followed by senior analytical and advisory positions supporting strategic decision-making in R&D and commercial planning.
Ben specializes in quantitative analysis, leading projects covering buy and sell side due diligence, deal benchmarking, pipeline tracking, competitor analysis and product forecasting across a broad range of indications and markets, with an increasing focus on rare diseases. Recent work has included building prioritization models that can be used to identify in-licensing opportunities, out licensing partners, attractive indications, or technologies. Ben has authored multiple peer-reviewed journal articles and industry standard guideline documents.
As a neuroscientist, consultant and commercial leader, Kelly brings more than 16 years of experience in the life sciences sector. She partners with insights, analytics, and commercial strategy teams to transform how pharmaceutical organizations capture and operationalize market intelligence. At Evaluate, Kelly focuses on creative solutioning, bringing together life science consultants, data scientists, and subject‑matter experts to build custom intelligence programs and products that leverage the full breadth of Norstella’s assets, including gold-standard forecasting, real‑world data, market access insights, and expert journalistic intelligence. With expertise in competitive landscape analysis, tech-enabled secondary monitoring, primary research, and comprehensive conference coverage, her work supports translation of complex market signals into clear, actionable insights. Kelly holds a PhD in Neuroscience from Georgetown University and completed a postdoctoral fellowship at the National Institute of Neurological Disorders and Stroke (NINDS).
Markella brings 20 years of industry and consulting experience, with deep knowledge and expertise in oncology, rare disease and ophthalmology. She specializes in CI landscaping projects in specialty indications and has led our largest CI monitoring projects since 2020. She has led Norstella’s largest conference coverage engagements with Top 10 Pharma clients and brings on-the-ground, secondary and primary CI expertise. She holds an MBA from Baruch College and a master’s in biotechnology from Columbia University.
Get in touch with our team to explore the right solutions for your business.
